Equity Research, Broker Reports, and media content on VISTIN PHARMA AS

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about VISTIN PHARMA AS
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
Login

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on VISTIN PHARMA AS. We currently have 0 research reports from 0 professional analysts.

Open
0.00
Volume
0.0m
Range Today
0.00/0.00
52 Week
0.00/0.00
Market Cap
0m
Enterprise Value
n/am
Pension Liability
# Shares
0m
Latest PE (hist)
Div Yield

Latest News/RNS

(more news)
Date Source Announcement
26Apr18 06:01 GNW Vistin Pharma ASA : Delivers 22% revenue growth in first quarter 2018
22Mar18 15:36 GNW Vistin Pharma ASA : UPDATE ON THE ENERGY TRADING BUSINESS
16Mar18 09:47 GNW Vistin Pharma ASA : Torbjørn Kjus joins Vistin to develop new business area
27Feb18 06:00 GNW Vistin Pharma ASA : Fourth quarter 2017 results
09Oct17 13:33 GNW Vistin Pharma ASA : Proposal for Extraordinary Dividend
02Oct17 09:28 GNW Vistin Pharma ASA : Sale of Opioids and CMO business completed
31Aug17 06:00 GNW Vistin Pharma ASA : Second quarter 2017 results - continuing strong demand for metformin
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    VISTIN PHARMA AS

  • Providers covering

    VISTIN PHARMA AS

  • 04 Jun 18

The Monthly

Hardman & Co recently welcomed Milan Radia to our roster of established, industry expert analysts. Milan has 25 years of equity market experience at major investment banks and in asset management, and has worked on many high-profile successful IPOs. In 2017, he was ranked the No.1 earnings estimator in the UK for his sector in the Thomson Starmine Awards. Milan has also been techMARK Analyst of the Year and achieved top three Institutional Investor sector rankings for his coverage of the software and telecoms sectors. In our lead article this month he gives an insight into his thinking on some key themes in the sector.

Companies: OPM ABZA AVO AGY APH ARBB AVCT BNO BUR CMH CLIG COS DNL EVG GTLY GDR INL KOOV MCL MUR NSF OXB NIPT PHP RE/ REDX SCLP SCE SIXH TRX TON VAL

  • 19 Jun 18

Volatility returns

When we last published the FTSE 100 was reaching an all-time high of 7877. We have subsequently seen increased volatility and some of the previous progress made by markets surrendered. The escalation of the potential trade war between the US and China and the imposition of more tariffs has unnerved markets. At home, we have continued to see M&A activity. While company results have largely been as anticipated, the outlook in some sectors looks less promising. In Share News & Views, we comment on Aortech*, ECSC*, Location Sciences*, Norcros, NWF, Tricorn* and Warpaint London*.

Companies: AOR APC BMS CRPR DMTR ECSC ESC EUSP FDM GETB LSAI SNX SPRP TCN W7L

  • 12 Jun 18

New projects to drive shareholder value

AorTech has raised a gross total of £2.6m to fund two new projects. As a licensing and royalty business of its patented Elast-Eon technology, AorTech has been marginally EBITDA positive. We believe there is substantial potential share price upside as, in our view, each of the new projects could create £50m of shareholder value. Textiles (patches and grafts) should have initial sales within two years while heart valves will potentially progress to a licensing stage in a similar timeframe. We initiate coverage with a 400p TP and Buy rating.

Companies: Aortech International
  • 27 Apr 18

Positive trading update

A trading update for the year to 30 April 2018 points to better-than-expected revenue growth as well as the benefits of a reduced tax charge, reflecting increased R&D tax credits for FY 2018 and a re-assessment of FY 2017 claims. We now expect Scientific Digital Imaging to report revenues of £14.1m, an increase of 31%, c.11% of which arises from a full year’s contribution from the Astles acquisition. This is 2% (£0.33m) higher than previously forecast and is attributed to strong demand from both Sentek (single-use electrodes) and Atik Cameras. We upgrade our forecast for FY 2018 adjusted EPS by 7% (5% attributed to lower tax charge), but given our current thoughts as to the recurring nature of these revenues, we have left our FY 2019 forecasts broadly unchanged. We raise our target price to 37p, which is based on rolling forward multiples to FY 2019. At this level, the stock would trade on EV/Sales of 2.1x, EV/EBITDA of 10.0x and adjusted P/E of 16.3x.

Companies: Scientific Digital Imaging
  • 22 May 18

The rise of the exosome

ReNeuron introduced its exosome nanomedicine programme at its recent capital markets day. While being a preclinical programme, it has three significant advantages. First, it gives ReNeuron the potential to expand into new therapeutic indications. Second, it opens up the potential for collaborations in diagnostics and drug delivery. Third, it builds on its wealth of experience and IP and on its CTX cell line on which ReNeuron’s existing products and the exosome platform are built.

Companies: Reneuron Group
  • 14 Jun 18

First insight into Pharmaxis LOXL2 Phase I data

First insights into Pharmaxis’ Phase I safety data of its anti-fibrotic LOXL2 inhibitor programme, in which Synairgen retains a 17% interest in all future financial payments, shows that Pharmaxis is on track to license this asset in H2 2018. Pharmaxis informed potential partners attending the recent BIO 2018 conference in Boston on data emerging from the Phase I clinical studies, which have demonstrated a best in class profile and clean safety profile. The Phase I trial and Phase II-enabling toxicity studies are due to complete in Q3 2018 with final commercial partnering discussions to follow. We retain a 35p target price, based on a sum-of-the-parts riskadjusted DCF, which would rise by c.28p and c.9p on successful completion of upcoming safety data for Synairgen’s inhaled interferon beta for COPD (SNG001) and LOXL2, respectively.

Companies: Synairgen
  • 21 Jun 18

Trading ahead of expectations

The provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, has confirmed that based on its current unaudited accounts, it is trading ahead of market expectations for its full financial year ended 30th June 2018. The Company’s anticipated total income for the full year is likely to be greater than £495k (we were forecasting £450k) and its anticipated loss will be materially reduced compared to current market expectations. We were previously anticipating a pre-tax loss of £0.34m.

Companies: Physiomics
  • 28 Nov 16

Worst-case scenario averted

The court ruling upholding the validity of the Orexo ’996 Zubsolv patent precludes Actavis from launching a generic before September 2019. Orexo has 30 days to decide whether to appeal the court decision that a second patent (’330 with 2032 expiry) is invalid. A worst-case scenario allowing imminent launch of Actavis generic(s) has been averted. Zubsolv’s IP portfolio includes two additional patents (’900 and ’421) that extend to 2032, which coupled with the prospect of an appeal on ’330, means that significant hurdles remain ahead of Actavis generic launch.

Companies: Orexo
  • 02 Mar 17

N+1 Singer - All creatures great and small - An overview of the animal health sector

Animal Health is a vast market with multiple long-term growth characteristics and opportunities. In this report we have outlined valuations, M&A activity and the key growth drivers in two animal health subsectors: companion animal health and livestock health. Although the commercial positioning of the eight companies covered in this report (Animalcare, Anpario, Benchmark Holdings, CVS Group, Dechra, ECO Animal Health, Genus and Pets at Home) differ significantly, all have exposure to positive market trends.

Companies: GNS ANCR CVSG DPH BMK EAH ANP PETS

  • 18 May 17

Clinigen Group PLC - A Global Leader in Access to Medicines

Clinigen capitalizes on the high unmet need to access prescription medicines in niche markets characterized by a limited presence of traditional medicine distribution channels.

Companies: Clinigen Group
  • 12 Sep 17

Growth achieved despite project deferral. Cleaner business now better positioned to execute.

The growing Contract Research Organisation has published H1 June 2017 results. Despite the deferral of a late phase project into Q1 2018 VENN still managed to deliver 1% revenue growth to €9.15m and EBITDA growth of €0.414m. Growth was further held back by an underperformance of elements of the early-phase part of the business. However, infrastructure and systems are now largely complete and Venn is confident of its ability to execute new business opportunities leveraging its full drug development lifecycle range of services and to reduce the concentration risk of business weighting amongst its top 10 clients.

Companies: Venn Life Sciences
  • 11 Oct 17

Aim Journal

The Quoted Companies Alliance has set out its proposals for taxation ahead of next month’s Budget. The smaller company pressure group believes that the UK needs to build a post-EU tax regime that supports and incentivises smaller companies. One of the key aspects of the proposals is a levelling of the playing field between debt and equity. At the moment, a company can claim tax relief for costs incurred in raising debt but not the costs of a share issue. The QCA believes that the government should encourage long-term equity finance.

Companies: ITX CLIN OPM STEL PEN KAPE

  • 26 Jan 18

Interims underpin FY 2018 forecasts

Scientific Digital Imaging reported strong interim results to 31 October 2017, with a 34% increase in revenues and adjusted EPS of 1.22p (+74%). Results included a first-time contribution from Astles and ATC, which contributed £1.1m (67%) to revenue growth. Legacy businesses also grew, by a commendable 11%. Despite this, we leave forecasts unchanged given that H1 included a one-off licence payment (£0.15m) that boosted underlying profits, without which EPS growth was 50%. These results, however, clearly demonstrate the improved free cashflows, driven by high-margin profitable businesses (c.20% EBITDA margin). Our target price and forecasts are unchanged, although both look exposed to upgrades based on the prospect of sustained strong underlying trading and additional EPS-enhancing acquisitions that the company is currently reviewing.

Companies: Scientific Digital Imaging
  • 26 Jan 18

The year of the Great Exhibition

2018 is the year of the Great Exhibition of the North. This summer, Newcastle and Gateshead will play host to a government-sponsored, 80-day marathon of events. Billed as the largest event in England this year, the Great Exhibition will showcase the best of the North East’s art, culture, design and innovation and we expect it to highlight the region’s ongoing success in high-end engineering, technology and life sciences. It may also reflect on the success of the North East’s plcs, the most striking example of which is Sage’s transition from 1980’s start-up to £9bn FTSE100 stalwart. We remain on the look out for the next Sage and expect the region to continue to produce attractive IPO candidates following Ramsdens’ success last year. Overall 2017 was a positive year for the region’s listed companies, one highlight of which was the takeover of Quantum Pharma, an N+1 Singer client, by Clinigen for £150m. We are confident that 2018 will be another successful year. Our top regional picks this year are Hargreaves Services, Zytronic and Applied Graphene Materials.

Companies: AGM BWY GRI GRG HSP IDH KMK NTG RFX UTW VNET ZYT

  • 02 Feb 18

QSI acquisition and upgrades

SDI is acquiring Quantum Scientific Imaging (QSI), a manufacturer and supplier of high-performance cameras that have applications in the astronomy and life sciences fields. Considered a bolt-on acquisition, it will be incorporated into SDI’s Atik Cameras business. SDI is paying £246k ($350k) for the assets, trademarks and patents of QSI, representing prospective EV/Sales of 0.7x. The acquisition is being funded by SDI’s recently enlarged banking facility. We expect the acquisition to be 2% accretive to adjusted EPS in FY 2019. We are raising our target price by 6% to 34p, which places SDI on a CY 2018 P/E of 15.3x and EV/EBITDA of 9.7x.

Companies: Scientific Digital Imaging